PDF(Pubmed)
Abstract：
UNASSIGNED: The COVID-19 pandemic has had a significant impact on the management and care of onco-hematological patients, particularly those with lymphoproliferative disorders who are at higher risk for COVID-19 associated bacterial and fungal superinfections.
UNASSIGNED: We present the successful treatment of a 44-year-old male patient with refractory mantle cell lymphoma treated with chimeric antigen receptor T (CAR-T) cell therapy, despite concurrent COVID-19 infection. The patient developed grade II cytokine release syndrome, requiring admission to the intensive care unit. The CAR-T cells expanded effectively, and the patient achieved complete metabolic remission. During the treatment course, the patient experienced complications including COVID-19-associated pulmonary aspergillosis and a co-infection with Stenotrophomonas maltophilia and the SARS-CoV-2 omicron variant. Prompt antifungal and antibacterial therapy, along with appropriate COVID-19 treatment, led to the resolution of these infections. Dexamethasone was also administered to reduce inflammation and aid hematologic recovery. Despite the presence of multiple infections, the patient achieved complete remission of lymphoma, highlighting the effectiveness of CAR-T cell therapy in this high-risk patient.
UNASSIGNED: Despite the challenges posed by concurrent infections, the decision to proceed with CAR-T cell therapy in this patient proved to be successful, resulting in complete remission of lymphoma. Early initiation of supportive therapies and the use of dexamethasone contributed to the resolution of complications. This case underscores the importance of individualized decision-making and the potential benefits of CAR-T cell therapy in similar high-risk patients.
UNASSIGNED: We present the successful treatment of a 44-year-old male patient with refractory mantle cell lymphoma treated with chimeric antigen receptor T (CAR-T) cell therapy, despite concurrent COVID-19 infection. The patient developed grade II cytokine release syndrome, requiring admission to the intensive care unit. The CAR-T cells expanded effectively, and the patient achieved complete metabolic remission. During the treatment course, the patient experienced complications including COVID-19-associated pulmonary aspergillosis and a co-infection with Stenotrophomonas maltophilia and the SARS-CoV-2 omicron variant. Prompt antifungal and antibacterial therapy, along with appropriate COVID-19 treatment, led to the resolution of these infections. Dexamethasone was also administered to reduce inflammation and aid hematologic recovery. Despite the presence of multiple infections, the patient achieved complete remission of lymphoma, highlighting the effectiveness of CAR-T cell therapy in this high-risk patient.
UNASSIGNED: Despite the challenges posed by concurrent infections, the decision to proceed with CAR-T cell therapy in this patient proved to be successful, resulting in complete remission of lymphoma. Early initiation of supportive therapies and the use of dexamethasone contributed to the resolution of complications. This case underscores the importance of individualized decision-making and the potential benefits of CAR-T cell therapy in similar high-risk patients.
摘要：
■COVID-19大流行对血液病患者的管理和护理产生了重大影响，特别是那些患有淋巴增生性疾病的人，他们患COVID-19相关的细菌和真菌超感染的风险更高。
■我们介绍了用嵌合抗原受体T（CAR-T）细胞疗法治疗的一名44岁男性难治性套细胞淋巴瘤患者的成功治疗方法。尽管并发COVID-19感染。患者出现II级细胞因子释放综合征,需要进入重症监护室。CAR-T细胞有效扩增，患者实现了代谢完全缓解。在治疗过程中，患者出现并发症,包括COVID-19相关肺曲霉病,以及嗜麦芽窄食单胞菌和SARS-CoV-2omicron变异型合并感染.及时进行抗真菌和抗菌治疗，加上适当的COVID-19治疗，导致了这些感染的解决。还施用地塞米松以减少炎症和帮助血液学恢复。尽管存在多种感染，患者淋巴瘤完全缓解,强调CAR-T细胞疗法在该高危患者中的有效性。
■尽管并发感染带来了挑战，对这名患者进行CAR-T细胞治疗的决定被证明是成功的，导致淋巴瘤完全缓解。早期开始支持疗法和使用地塞米松有助于解决并发症。这一案例强调了个性化决策的重要性以及CAR-T细胞疗法在类似高危患者中的潜在益处。
■我们介绍了用嵌合抗原受体T（CAR-T）细胞疗法治疗的一名44岁男性难治性套细胞淋巴瘤患者的成功治疗方法。尽管并发COVID-19感染。患者出现II级细胞因子释放综合征,需要进入重症监护室。CAR-T细胞有效扩增，患者实现了代谢完全缓解。在治疗过程中，患者出现并发症,包括COVID-19相关肺曲霉病,以及嗜麦芽窄食单胞菌和SARS-CoV-2omicron变异型合并感染.及时进行抗真菌和抗菌治疗，加上适当的COVID-19治疗，导致了这些感染的解决。还施用地塞米松以减少炎症和帮助血液学恢复。尽管存在多种感染，患者淋巴瘤完全缓解,强调CAR-T细胞疗法在该高危患者中的有效性。
■尽管并发感染带来了挑战，对这名患者进行CAR-T细胞治疗的决定被证明是成功的，导致淋巴瘤完全缓解。早期开始支持疗法和使用地塞米松有助于解决并发症。这一案例强调了个性化决策的重要性以及CAR-T细胞疗法在类似高危患者中的潜在益处。
